Merck & Co Inc Investor Day (Virtual) Transcript
Good morning. I'm Peter Dannenbaum, Head of Investor Relations for Merck. Thank you for joining today's virtual investor event. We look forward to providing you with insight into Merck's spin-off of Organon, which will soon be operating as an independent company. As you can see, we have a full agenda, beginning with Rob Davis, who will describe the transaction from Merck's perspective.
You will then hear from the Organon leadership team, who will describe our business strategy and growth opportunities. I'm Jennifer Halchak, and as the newly appointed lead for Investor Relations at Organon, I know I speak for the team when I say we are really looking forward to today's event.
Kevin Ali, Organon's CEO, will kick this off with a high-level strategic overview. And he will be followed by business leaders, who will highlight the opportunities they see in each of their respective areas of responsibility. Matt Walsh, Organon's CFO, will also provide a financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
